- Home
- NAOV vs BLUWW Comparison
NAOV vs BLUWW Comparison
Compare NAOV & BLUWW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAOV
- BLUWW
- Stock Information
- Founded
- NAOV 2003
- BLUWW N/A
- Country
- NAOV United States
- BLUWW United States
- Employees
- NAOV N/A
- BLUWW N/A
- Industry
- NAOV Industrial Specialties
- BLUWW
- Sector
- NAOV Health Care
- BLUWW
- Exchange
- NAOV Nasdaq
- BLUWW Nasdaq
- Market Cap
- NAOV 2.1M
- BLUWW 1.8M
- IPO Year
- NAOV N/A
- BLUWW 2025
- Fundamental
- Price
- NAOV $5.37
- BLUWW $0.12
- Analyst Decision
- NAOV
- BLUWW
- Analyst Count
- NAOV 0
- BLUWW 0
- Target Price
- NAOV N/A
- BLUWW N/A
- AVG Volume (30 Days)
- NAOV 46.6K
- BLUWW N/A
- Earning Date
- NAOV 08-19-2025
- BLUWW N/A
- Dividend Yield
- NAOV N/A
- BLUWW N/A
- EPS Growth
- NAOV N/A
- BLUWW N/A
- EPS
- NAOV N/A
- BLUWW N/A
- Revenue
- NAOV $2,339,000.00
- BLUWW N/A
- Revenue This Year
- NAOV N/A
- BLUWW N/A
- Revenue Next Year
- NAOV N/A
- BLUWW N/A
- P/E Ratio
- NAOV N/A
- BLUWW N/A
- Revenue Growth
- NAOV N/A
- BLUWW N/A
- 52 Week Low
- NAOV $5.00
- BLUWW N/A
- 52 Week High
- NAOV $162.50
- BLUWW N/A
- Technical
- Relative Strength Index (RSI)
- NAOV 28.41
- BLUWW N/A
- Support Level
- NAOV $5.00
- BLUWW N/A
- Resistance Level
- NAOV $5.65
- BLUWW N/A
- Average True Range (ATR)
- NAOV 0.78
- BLUWW 0.00
- MACD
- NAOV -0.14
- BLUWW 0.00
- Stochastic Oscillator
- NAOV 9.74
- BLUWW 0.00
About NAOV NanoVibronix Inc.
NanoVibronix Inc manufactures noninvasive biological response-activating devices that target biofilm prevention, pain therapy, and wound healing and can be administered at home, without the assistance of medical professionals. Its primary products are UroShield; PainShield; and WoundShield. Each of its UroShield, PainShield, and WoundShield products employs a small, disposable transducer that transmits low-frequency, low-intensity ultrasound acoustic waves that seek to repair and regenerate tissue, musculoskeletal and vascular structures, and decrease biofilm formation on urinary catheters and associated urinary tract infections. The company derives revenues from selling its products directly to patients, through distributor agreements.